The standard first-line therapy for SCLC consists of chemotherapy (cisplatin or carboplatin with etoposide) in combination with immunotherapy (antibodies to programmed cell death protein 1 (PD1), and antibodies to PD1 ligand 1 (PD-L1)) (Zugazagoitia and Paz-Ares, 2022). This evidence concerns the gene PDCD1 and small cell lung carcinoma.